Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00
Debt
Debt-to-Equity RatioN/A
Current Ratio7.18
Quick Ratio7.17
Price-To-Earnings
Trailing P/E Ratio-10.68
Forward P/E Ratio-11.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.72 million
Price / Sales36.62
Cash FlowN/A
Price / CashN/A
Book Value$7.96 per share
Price / Book3.73
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-337.45%
Return on Equity-37.45%
Return on Assets-31.83%
Miscellaneous
Employees135
Outstanding Shares41,600,000
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.01. The biotechnology company had revenue of $8.07 million for the quarter, compared to analysts' expectations of $9.53 million. Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
6 brokerages have issued 1-year price objectives for Cellectis' shares. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' share price to reach $44.80 in the next year. View Analyst Ratings for Cellectis.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI).
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika Ph.D., Co-Founder, Chairman and Chief Exec. Officer (Age 53)
- Dr. David J. D. Sourdive Ph.D., Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
- Mr. Eric Dutang, Chief Financial Officer (Age 44)
- Ms. Elsy Boglioli, Chief Operating Officer
- Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 55)
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
Has Cellectis been receiving favorable news coverage?
Media coverage about CLLS stock has trended somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.14 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Cellectis' major shareholders?
Cellectis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nexthera Capital LP (0.80%), BlackRock Inc. (0.30%), Point72 Asset Management L.P. (0.17%), JPMorgan Chase & Co. (0.16%), Bellevue Group AG (0.13%) and Jane Street Group LLC (0.12%). View Institutional Ownership Trends for Cellectis.
Which major investors are selling Cellectis stock?
Which major investors are buying Cellectis stock?
CLLS stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Point72 Asset Management L.P., Jane Street Group LLC, JPMorgan Chase & Co., Bellevue Group AG, A.R.T. Advisors LLC, Wells Fargo & Company MN and Trellus Management Company LLC. View Insider Buying and Selling for Cellectis.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $29.68.
How big of a company is Cellectis?
Cellectis has a market capitalization of $1.28 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 135 workers across the globe.
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
